发明申请
US20080286312A1 Membrane-anchored beta2 microglobulincovalently linked to MHC class I peptide epitopes
审中-公开

基本信息:
- 专利标题: Membrane-anchored beta2 microglobulincovalently linked to MHC class I peptide epitopes
- 专利标题(中):膜锚定的β2微球蛋白与MHC I类肽表位共价连接
- 申请号:US11541566 申请日:2006-10-03
- 公开(公告)号:US20080286312A1 公开(公告)日:2008-11-20
- 发明人: Gideon Gross , Alon Margalit
- 申请人: Gideon Gross , Alon Margalit
- 申请人地址: IL Kiryat Shmona
- 专利权人: Gavish-Galilee Bio Applications Ltd.
- 当前专利权人: Gavish-Galilee Bio Applications Ltd.
- 当前专利权人地址: IL Kiryat Shmona
- 主分类号: A61K39/00
- IPC分类号: A61K39/00 ; C07H21/00 ; C12N15/63 ; A61P37/02 ; C12N5/00
摘要:
The invention provides a polynucleotide comprising a sequence encoding a polypeptide that is capable of high level presentation of antigenic peptides on antigen-presenting cells, wherein the polypeptide comprises a β2-microglobulin molecule that is linked through its carboxyl terminal to a bridge peptide which spans the whole distance to the cell membrane, said bridge peptide being linked to a polypeptide stretch consisting of the full or partial transmembrane and/or cytoplasmic domains selected from the group consisting of a toll-like receptor (TLR) polypeptide, a CD40 polypeptide, and TLR and CD40 polypeptides fused in tandem, that allows the anchorage of the β2-microglobulin molecule to the cell membrane, and through its amino terminal to at least one antigenic peptide comprising an MHC class I epitope, wherein said antigenic peptide is preferably derived from a tumor-associated antigen or from a pathogenic antigen. Antigen presenting cells and DNA and cellular vaccines for treatment of cancer and infectious diseases, are also provided.
摘要(中):
本发明提供了一种多核苷酸,其包含编码能够在抗原呈递细胞上高水平呈递抗原肽的多肽的序列,其中所述多肽包含通过其羧基末端连接到桥接肽的β2-微球蛋白分子,所述桥肽跨越 所述桥肽与由全部或部分跨膜和/或细胞质结构域组成的多肽延伸连接,所述全部或部分跨膜和/或细胞质结构域选自一种toll样受体(TLR)多肽,CD40多肽和TLR 和CD40多肽共同融合,其允许β2-微球蛋白分子锚定于细胞膜,并通过其氨基末端至少包含MHC I类表位的抗原肽,其中所述抗原肽优选衍生自肿瘤 相关抗原或来自致病性抗原。 还提供抗原呈递细胞和用于治疗癌症和感染性疾病的DNA和细胞疫苗。
IPC结构图谱:
A | 人类生活必需 |
--A61 | 医学或兽医学;卫生学 |
----A61K | 医用、牙科用或梳妆用的配制品 |
------A61K39/00 | 含有抗原或抗体的医药配制品 |